Protection induced by early stage vaccination with pandemic influenza virus-like particles

Lee, Gi-Ja; Quan, Fu‐Shi

doi:10.1016/j.vaccine.2016.06.011

Cited by 5 publications

(3 citation statements)

References 35 publications

(50 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A goal of vaccination is to generate long-lived memory B cells that can rapidly differentiate into ASCs upon re-exposure to antigens [18,19,23]. To determine influenza virus-specific antibody secreting cell responses, cells from the spleens and lungs were collected and incubated 5 days in 96 well plate coated with avian influenza A/Viet Nam/1203/2004(rgH5N1) inactivated virus.…”

Section: Resultsmentioning

confidence: 99%

Influenza M2 virus-like particle vaccination enhances protection in combination with avian influenza HA VLPs

et al. 2019

Self Cite

View full text Add to dashboard Cite

Despite the ability to induce a broad range of cross protection, M2e5x virus-like particles (VLPs) alone provide limited vaccine efficacy and confer low efficacy of protection against highly pathogenic avian influenza virus (HPAIV) infection in chickens. Avian influenza hemagglutinin (HA) has been a major antigenic target that enhances humoral immunity, but the efficacy of avian HA-based vaccines against HPAIV needs to be further improved. In this study, we evaluated the vaccine efficacy induced by combination of conserved tandem repeat M2e5x VLPs and HA VLPs against an avian influenza virus. We found that combinatorial vaccine elicited higher levels of reassortant H5N1 (rgH5N1) virus-specific IgG, IgG1, IgG2a and IgA antibody responses compared to M2e5x VLPs in sera and lungs of mice. Combinatorial VLPs vaccination induced higher levels of CD8 + T cell and germinal center B cell responses in lung and spleen compared to M2e5x VLPs. Combinatorial VLPs vaccination showed significantly reduced inflammatory responses and lung viral loads upon rgH5N1 virus challenge infection, resulting in less body weight loss compared to M2e5x VLPs alone. These results indicate that immune responses to both M2e and HA might provide a strategy of vaccination inducing enhanced protection against avian influenza virus.

show abstract

Section: Resultsmentioning

confidence: 99%

Influenza M2 virus-like particle vaccination enhances protection in combination with avian influenza HA VLPs

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…In addition, we assumed that the effects of the COVID-19 vaccine would be similar to those of influenza A, influenza B, or measles vaccine in the scenario I. Most studies indicated that the time of development of influenza immunity ranged between 7 and 14 days [ 33 – 35 ]. Meanwhile, the highest rate of immunoglobulin G positivity in measles occurred in weeks 4 and 5 post-vaccination [ 36 , 37 ].…”

Section: Methodsmentioning

confidence: 99%

The optimal vaccination strategy to control COVID-19: a modeling study in Wuhan City, China

et al. 2021

View full text Add to dashboard Cite

Background Reaching optimal vaccination rates is an essential public health strategy to control the coronavirus disease 2019 (COVID-19) pandemic. This study aimed to simulate the optimal vaccination strategy to control the disease by developing an age-specific model based on the current transmission patterns of COVID-19 in Wuhan City, China. Methods We collected two indicators of COVID-19, including illness onset data and age of confirmed case in Wuhan City, from December 2, 2019, to March 16, 2020. The reported cases were divided into four age groups: group 1, ≤ 14 years old; group 2, 15 to 44 years old; group 3, 44 to 64 years old; and group 4, ≥ 65 years old. An age-specific susceptible-exposed-symptomatic-asymptomatic-recovered/removed model was developed to estimate the transmissibility and simulate the optimal vaccination strategy. The effective reproduction number (Reff) was used to estimate the transmission interaction in different age groups. Results A total of 47 722 new cases were reported in Wuhan City from December 2, 2019, to March 16, 2020. Before the travel ban of Wuhan City, the highest transmissibility was observed among age group 2 (Reff = 4.28), followed by group 2 to 3 (Reff = 2.61), and group 2 to 4 (Reff = 1.69). China should vaccinate at least 85% of the total population to interrupt transmission. The priority for controlling transmission should be to vaccinate 5% to 8% of individuals in age group 2 per day (ultimately vaccinated 90% of age group 2), followed by 10% of age group 3 per day (ultimately vaccinated 90% age group 3). However, the optimal vaccination strategy for reducing the disease severity identified individuals ≥ 65 years old as a priority group, followed by those 45–64 years old. Conclusions Approximately 85% of the total population (nearly 1.2 billion people) should be vaccinated to build an immune barrier in China to safely consider removing border restrictions. Based on these results, we concluded that 90% of adults aged 15–64 years should first be vaccinated to prevent transmission in China. Graphical Abstract

show abstract

“…Major successes in research on influenza vaccines have helped to develop new technologies that have achieved the reduction of production time or increased the performance of the antigen [21]. To achieve this, various substrates and conditions for production of the antigen were developed [22][23][24][25][26][27], thus obtaining recombinant vaccines [28,29], virus-like particles [30,31] and viral-vectored vaccines [32] all of these strategies start from a characterized virus or nucleotide sequence, from which viral particles or proteins that constitute the vaccine antigen are generated.…”

mentioning

confidence: 99%

The Future of Influenza Vaccines: Developing Tools to Match Glycosylation Patterns Relevant for Protection

Carlos¹,

Alberto²,

Jorge³

2016

J Vaccines Vaccin

View full text Add to dashboard Cite

Influenza is a viral disease that is easily transmissible, and it is found around the world and can affect anyone regardless of their age group. There are 3 types of influenza viruses: A, B and C. Influenza viruses A and B are usually responsible for causing outbreaks of influenza from limited to major epidemics or even pandemics. The main preventive measure against this virus is annual vaccination, and the World Health Organization annually publishes recommendations for the production of influenza vaccines, but the protection observed so far has not been optimal. It has been proven that using egg as a substrate for vaccine production causes changes in the structure of proteins on the surface of influenza virus, and these changes could be involved in the low effectiveness of vaccines against influenza. Here we comment about platforms currently used to produce viruses for inclusion into influenza vaccines, and suggest alternatives to improve glycosylation patterns to resemble more closely those found in viruses infecting human beings, aiming to improve the effectiveness of protection conferred by these new vaccines.

show abstract

Protection induced by early stage vaccination with pandemic influenza virus-like particles

Cited by 5 publications

References 35 publications

Influenza M2 virus-like particle vaccination enhances protection in combination with avian influenza HA VLPs

Influenza M2 virus-like particle vaccination enhances protection in combination with avian influenza HA VLPs

The optimal vaccination strategy to control COVID-19: a modeling study in Wuhan City, China

The Future of Influenza Vaccines: Developing Tools to Match Glycosylation Patterns Relevant for Protection

Contact Info

Product

Resources

About